Jupiter Neurosciences Inc. (NASDAQ: JUNS), a clinical-stage pharmaceutical company known for developing JOTROL, an enhanced orally administered resveratrol formulation, has launched Nugevia, a direct-to-consumer longevity product line. The line focuses on mitochondrial support, mental clarity, and beauty from within, with cognitive health as a central component. The company expects Nugevia to account for about 60% of its sales by volume, driven primarily by the Nugevia MND supplement, which is designed to protect and enhance cognitive function.
“Brain health is central to Jupiter’s DNA as a neuroscience company, and consumer awareness in this area is accelerating rapidly,” said a Jupiter Neurosciences spokesperson. “Our Nugevia MND formulation directly builds on our pharmaceutical expertise in neuroinflammation and CNS function, making it the most natural bridge between our clinical work and consumer wellness line.” The spokesperson highlighted the growing demand for cognitive support due to aging populations and proactive consumers seeking mental clarity, focus, and resilience.
The global brain health supplement market is projected to reach approximately $23 billion by 2030, growing at a CAGR of around 13%. Jupiter Neurosciences brings its deep history in brain disease research to this market, having developed drugs for neuroinflammation and CNS disorders such as Alzheimer's and Parkinson's. The Nugevia line includes MND, GLO, and PWR formulations, all derived from JOTROL.
JOTROL is designed to deliver therapeutically relevant levels of resveratrol, achieving about nine times higher absorption and proven CNS penetration. Resveratrol activates PARP-1, a protein involved in DNA repair, and offers antioxidant, anti-inflammatory, and cognitive benefits. A phase one trial showed JOTROL was safe and well-tolerated, with blood plasma levels 8-10-fold higher than naïve resveratrol. Phase two trials focus on Alzheimer’s, Parkinson’s, and other CNS disorders. The technology is patented in the U.S., Europe, China, Hong Kong, and Japan through 2036.
What differentiates Nugevia from other supplements is its precision-engineered “intelligent stacking” of synergistic compounds to enhance cellular resilience, support blood-brain barrier delivery, and promote system-wide optimization. The company has enlisted brand ambassadors including former tennis star Annika Sörenstam, NBA legend Chris Webber, scientist Charbel Moussa, and biohacker Jean Fallacar to demonstrate the product’s benefits across diverse lifestyles.
“Jupiter Neurosciences is first and foremost a clinical-stage biotech company that has spent the past decade developing therapies for complex central nervous system (CNS) disorders,” a company spokesperson said. “What makes our entry into the supplement space so unique is that we’re coming into it from the clinic, not the other way around. It’s a natural evolution of our dual-path strategy: advancing prescription therapies for patients while empowering everyday consumers with credible, evidence-based solutions for healthy aging.”
This content was originally published on Benzinga and is for informational purposes only.
